NASDAQ:GNMX Aevi Genomic Medicine (GNMX) Stock Price, News & Analysis → The best inflation-proof investment (From DTI) (Ad) Free GNMX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.15▼$0.1850-Day Range$0.17▼$0.1952-Week Range$0.11▼$0.35Volume2.95 million shsAverage Volume3.16 million shsMarket Capitalization$12.89 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Aevi Genomic Medicine alerts: Email Address Ad Birch GoldBiden’s Sneaky H.R. 5376 Is A Nightmare For Retirement SaversFirst Obamacare For Health, Now Bidencare For 401(k)s - How To Optout>> Request Your FREE Info Kit << About Aevi Genomic Medicine Stock (NASDAQ:GNMX)Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease. The company also develops AEVI-005, which is in preclinical stage for the treatment of pediatric rare diseases. It has a strategic collaboration with Kyowa Hakko Kirin Co., Ltd. for an early stage monoclonal antibody program in an ultra-orphan pediatric indication. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.Read More Ad Birch GoldBiden’s Sneaky H.R. 5376 Is A Nightmare For Retirement SaversFirst Obamacare For Health, Now Bidencare For 401(k)s - How To Optout>> Request Your FREE Info Kit << GNMX Stock News HeadlinesFebruary 9, 2024 | benzinga.comPlc Astrazeneca's Net WorthSeptember 10, 2023 | thestreet.comAevi Genomic Medicine, Inc.May 7, 2024 | American Hartford Gold Group (Ad)Dave Ramsey Shocks Millions With US Dollar LunacyDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.March 11, 2023 | marketwatch.comForecast 2023-2027, Genomic Medicine Market: An Analysing Business Strategies and TrendsMarch 7, 2023 | finance.yahoo.comSucheta Bhatt, MD, FACMG and Rong Mao, MD, FACMG Elected to Board of Directors of the ACMG Foundation for Genetic and Genomic MedicineFebruary 24, 2023 | marketwatch.comThe Rise of Genomic Medicine Market Research 2023-2027: Opportunities and Challenges with Top Countries DataJanuary 30, 2023 | finance.yahoo.comNutritional Genomics Company, GenoPalate, Launches Personalized Supplement Line, GenoVitJanuary 26, 2023 | finanznachrichten.deGenomic Vision Strengthens Leadership Team With the Appointment of Frederic Hammel as Chief Operating OfficerMay 7, 2024 | American Hartford Gold Group (Ad)Dave Ramsey Shocks Millions With US Dollar LunacyDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.October 7, 2022 | finance.yahoo.comDante Genomics Unveils Digital Health Population Genomic Programs at the United Nations General Assembly Science SummitSee More Headlines Receive GNMX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aevi Genomic Medicine and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/01/2018Today5/07/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:GNMX Previous SymbolNASDAQ:MDGN CUSIPN/A CIK1138776 Webwww.aevigenomics.com Phone610-254-4201FaxN/AEmployees14Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,770,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-898.31% Return on Assets-286.73% Debt Debt-to-Equity RatioN/A Current Ratio0.65 Quick Ratio0.65 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.12 per share Price / Book1.38Miscellaneous Outstanding Shares77,714,000Free FloatN/AMarket Cap$12.89 million OptionableOptionable Beta1.13 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Michael F. Cola (Age 59)CEO, Pres & Director Mr. Brian D. Piper (Age 47)CFO & Corp. Sec. Dr. Garry A. Neil (Age 65)Chief Scientific Officer Key CompetitorsCoeptis TherapeuticsNASDAQ:COEPOrganovoNASDAQ:ONVOChromocell TherapeuticsNYSE:CHROBioCardiaNASDAQ:BCDATevogen BioNASDAQ:TVGNView All Competitors GNMX Stock Analysis - Frequently Asked Questions How were Aevi Genomic Medicine's earnings last quarter? Aevi Genomic Medicine, LLC (NASDAQ:GNMX) released its quarterly earnings data on Thursday, November, 1st. The biotechnology company reported ($0.12) EPS for the quarter, beating analysts' consensus estimates of ($0.15) by $0.03. What other stocks do shareholders of Aevi Genomic Medicine own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aevi Genomic Medicine investors own include Novavax (NVAX), Co-Diagnostics (CODX), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), iBio (IBIO), Immunomedics (IMMU), Actinium Pharmaceuticals (ATNM), Biocept (BIOC) and MEI Pharma (MEIP). This page (NASDAQ:GNMX) was last updated on 5/7/2024 by MarketBeat.com Staff From Our PartnersThe best inflation-proof investment DTIAI “wealth window” is closing June 25thParadigm PressCould Your Accounts Be Frozen?Allegiance GoldThe asset beating inflation by 4xColonial MetalsElon Musk Secret Crypto Plot ExposedCrypto 101 MediaHe Is Giving Away BitcoinCrypto Swap ProfitsMissed NVDA? Buy this AI stock NOWChaikin AnalyticsElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aevi Genomic Medicine, LLC Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
